Hanns U. Zeilhofer: Catalogue data in Autumn Semester 2023 |
| Name | Prof. Dr. Hanns U. Zeilhofer |
| Field | Pharmakologie |
| Address | Inst. f. Pharmazeutische Wiss. ETH Zürich, Y17 J 68 Winterthurerstrasse 190 8057 Zürich SWITZERLAND |
| Telephone | +41 44 635 59 12 |
| Fax | +41 44 635 59 88 |
| hansze@ethz.ch | |
| Department | Chemistry and Applied Biosciences |
| Relationship | Full Professor |
| Number | Title | ECTS | Hours | Lecturers | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 511-0000-00L | Drug Discovery and Development  | 2 credits | 1G + 2S | J. Hall, U. Thibaut, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer | |||||||||||||||||||||||
| Abstract | This course provides an overview over the concepts and processes employed in today's drug discovery and development. It has an introductory character but will also provide more detailed insights employing real life examples. The course combines lectures and interactive elements with active participation of the students. | ||||||||||||||||||||||||||
| Learning objective | Students - Understand the drug discovery process and can explain major approaches and relevant technical terms (for details see lecture notes). - Understand and appreciate the content and timing of drug development process steps, development phases and decision criteria. - Understand the concepts underlying drug product development through all the phases from preclinical and clinical development to regulatory submission, approval and market launch. - Can differentiate between small molecule drug development and biological drug development. - Understand the most important differences for drug development and approval between the EU and USA pharma markets with regard to legal and regulatory requirements. | ||||||||||||||||||||||||||
| Content | Course unit comprises weekly lectures covering the early phases of target and drug discovery (535-0901-01 S "From A to Z in Drug Discovery and Development I") with group work in the area of Drug Development (511-0000-00 G). The latter course lasts 2 full days (Days 1 and 2) and comprises both lectures and group work: inter alia an introduction to the entire suite of drug product development processes in the pharmaceutical industry, covering preclinical research and development, clinical development, regulatory processes and market launch. R&D support processes such as project management, quality management, pharmacovigilance and pharmacoeconomics will be covered as well as organizational and governance aspects of the pharmaceutical industry. In addition, important success factors for a later career in the pharmaceutical industry will be briefly discussed at the end of day 2 of the course. | ||||||||||||||||||||||||||
| Lecture notes | Will be published on "mystudies" | ||||||||||||||||||||||||||
| Literature | G. Nahler (Hrsg.) Dictionary of pharmaceutical medicine, Springer, Wien, 2013 (3rd edition) Further readings will be listed in the lecture notes. | ||||||||||||||||||||||||||
| Prerequisites / Notice | This course provides the essential basic knowledge required for the industry-specific modules of the spring semester. Safety conceptt: https://chab.ethz.ch/studium/bachelor1.html | ||||||||||||||||||||||||||
Competencies |
| ||||||||||||||||||||||||||
| 535-0001-00L | Introduction to Pharmaceutical Sciences I | 2 credits | 2V | J. Hall, S.‑D. Krämer, J.‑C. Leroux, B. Pfeiffer, U. Quitterer, J. Scheuermann, R. Schibli, Y. Yamauchi, H. U. Zeilhofer | |||||||||||||||||||||||
| Abstract | First identification with Pharmaceutical Sciences; motivation for profiling in the Natural Sciences, which are focused on within the first two years as a preparation for the specialized studies; sensitization for the duties and the responsibilities of a person with a federal diploma in Pharmacy; information about job opportunities. | ||||||||||||||||||||||||||
| Learning objective | First identification with Pharmaceutical Sciences; motivation for profiling in the Natural Sciences as a preparation for the specialized studies; sensitization for the duties and the responsibilities of a person with a federal diploma in Pharmacy; information about job opportunities. | ||||||||||||||||||||||||||
| Content | Introduction to Pharmaceutical Sciences by selected milestones of research and development. Overview on research activities at the Institute of Pharmaceutical Sciences that is focussed on drug delivery and development (from concepts to prototypes). Sensitization for communication skills and information management. Demonstration of job opportunities in community pharmacies, in the hospital, in industry, and in the public sector by experts in the different fields. | ||||||||||||||||||||||||||
| Lecture notes | Handouts for individual lectures. | ||||||||||||||||||||||||||
| Prerequisites / Notice | Interactive teaching | ||||||||||||||||||||||||||
| 535-0900-00L | Seminars on Drug Discovery and Development | 1 credit | 1K | R. Schibli, K. Eyer, C. Halin Winter, J. Hall, J.‑C. Leroux, U. Quitterer, G. Schneider, H. U. Zeilhofer | |||||||||||||||||||||||
| Abstract | State-of-the-art information on drug discovery and development by experts from academia and industry. | ||||||||||||||||||||||||||
| Learning objective | State-of-the-art information on drug discovery and development. | ||||||||||||||||||||||||||
| Content | Seminar series of the Institute of Pharmaceutical Sciences. Experts from academia and industry report on relevant topics. | ||||||||||||||||||||||||||
| 535-0901-00L | From A to Z in Drug Discovery and Development | 1 credit | 2S | J. Hall, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer | |||||||||||||||||||||||
| Abstract | The lecture series takes place at the ETH Hönggerberg and covers a variety of major activities involved in drug discovery: selecting drug targets, technologies used in drug discovery, small, medium and large drugs, objectives of the medicinal chemist, assessing drug safety, principles of personalized medicine, designing clinical trials, how intellectual property is protected, as well as others. | ||||||||||||||||||||||||||
| Learning objective | The objective of the course is to gain a global understanding of most of the important phases in the discovery and development of modern synthetic and biological drugs, from the first activities to clinical trials. The lecture is intended for students that have an interest in the area and/or may consider a career working in drug discovery. This lecture course complements knowledge and experience gained in the research project performed by the PhD student. | ||||||||||||||||||||||||||
| Content | Thirteen two hour lectures for life-science PhD students and students of the Pharmaceutical Sciences Master, given by experts from the ETH, UZH, USZ and the pharmaceutical industry. Introduction to the modern drug discovery process - Principles of drug pharmacokinetics and drug metabolism - Computer sciences in drug discovery - Drug targets - In vitro methods in drug discovery - Natural products in drug discovery - Medicinal chemistry: Chemical lead selection/optimization - Antibodies and therapeutic proteins: Targets and drugs - In vivo molecular imaging in drug discovery - Drug formulation: Key development consideration, Current new APIs challenges and FDA rising standards - Preclinical safety, adverse drug events and drug-drug interactions - Clinical development steps including trial design - Intellectual property in drug discovery and development | ||||||||||||||||||||||||||
| Literature | To be distributed during the lecture | ||||||||||||||||||||||||||
| Prerequisites / Notice | Formally none, but a basic understanding in biochemistry, physiology and chemistry is highly desirable as it will certainly help to get the most from the lectures. | ||||||||||||||||||||||||||